• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C3-杂芳酰基大麻素作为 CB2 大麻素受体的光标记配体。

C3-heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor.

机构信息

Department of Chemistry, University of Hawaii at Manoa, 2545 The Mall, Honolulu, HI 96822, USA.

出版信息

Bioorg Med Chem Lett. 2012 Aug 15;22(16):5322-5. doi: 10.1016/j.bmcl.2012.06.013. Epub 2012 Jun 15.

DOI:10.1016/j.bmcl.2012.06.013
PMID:22796181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3445631/
Abstract

A series of tricyclic cannabinoids incorporating a heteroaroyl group at C3 were prepared as probes to explore the binding site(s) of the CB1 and CB2 receptors. This relatively unexplored structural motif is shown to be CB2 selective with K(i) values at low nanomolar concentrations when the heteroaromatic group is 3-benzothiophenyl (41) or 3-indolyl (50). When photoactivated, the lead compound 41 was shown to successfully label the CB2 receptor through covalent attachment at the active site while 50 failed to label. The benzothiophenone moiety may be a photoactivatable moiety suitable for selective labeling.

摘要

一系列在 C3 位上引入杂芳酰基的三环大麻素被制备为探针,以探索 CB1 和 CB2 受体的结合部位。当杂芳基为 3-苯并噻吩基(41)或 3-吲哚基(50)时,该相对未探索的结构基序显示出对 CB2 的选择性,其 K(i) 值在低纳摩尔浓度下。当被光激活时,先导化合物 41 被证明能够通过在活性部位的共价结合成功标记 CB2 受体,而 50 则未能标记。苯并噻吩酮部分可能是适合选择性标记的光活化部分。

相似文献

1
C3-heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor.C3-杂芳酰基大麻素作为 CB2 大麻素受体的光标记配体。
Bioorg Med Chem Lett. 2012 Aug 15;22(16):5322-5. doi: 10.1016/j.bmcl.2012.06.013. Epub 2012 Jun 15.
2
Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.大麻素CB1和CB2受体的配体特异性以及CB2选择性激动剂的开发。
Curr Med Chem. 2008;15(14):1428-43. doi: 10.2174/092986708784567716.
3
Highly Selective, Amine-Derived Cannabinoid Receptor 2 Probes.高选择性、胺衍生的大麻素受体 2 探针。
Chemistry. 2020 Jan 27;26(6):1380-1387. doi: 10.1002/chem.201904584. Epub 2020 Jan 21.
4
Synthesis and testing of novel classical cannabinoids: exploring the side chain ligand binding pocket of the CB1 and CB2 receptors.新型经典大麻素的合成与测试:探索CB1和CB2受体的侧链配体结合口袋
Bioorg Med Chem. 2003 Jul 17;11(14):3121-32. doi: 10.1016/s0968-0896(03)00238-4.
5
CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches.基于建模和诱变方法的CB1和CB2大麻素受体结合研究。
Mini Rev Med Chem. 2005 Jul;5(7):651-8. doi: 10.2174/1389557054368754.
6
Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB/CB Receptor Interaction.三环吡唑类化合物作为大麻素 CB/CB 受体相互作用的有用支架。
Molecules. 2021 Apr 7;26(8):2126. doi: 10.3390/molecules26082126.
7
Preface.前言。
Methods Enzymol. 2017;593:xvii-xxiv. doi: 10.1016/S0076-6879(17)30257-4.
8
Combined CoMFA and CoMSIA 3D-QSAR study of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor.对苯并咪唑和苯并噻吩衍生物与CB2大麻素受体具有选择性亲和力的联合CoMFA和CoMSIA 3D-QSAR研究。
Eur J Pharm Sci. 2017 Apr 1;101:1-10. doi: 10.1016/j.ejps.2017.01.037. Epub 2017 Jan 28.
9
Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB, CB and CB/CB heteromer receptors.大麻素 CB、CB 和 CB/CB 杂二聚体受体作用的大麻二酚和大麻萜酚型植物大麻素的药理学数据。
Pharmacol Res. 2020 Sep;159:104940. doi: 10.1016/j.phrs.2020.104940. Epub 2020 May 26.
10
3'-functionalized adamantyl cannabinoid receptor probes.3'-官能化金刚烷基大麻素受体探针
J Med Chem. 2015 Apr 9;58(7):3104-16. doi: 10.1021/jm501960u. Epub 2015 Mar 20.

引用本文的文献

1
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.内源性大麻素系统作为治疗靶点的利弊:30 年的经验教训。
Pharmacol Rev. 2023 Sep;75(5):885-958. doi: 10.1124/pharmrev.122.000600. Epub 2023 May 10.
2
Covalent cannabinoid receptor ligands - structural insight and selectivity challenges.共价大麻素受体配体——结构洞察与选择性挑战。
RSC Med Chem. 2022 Apr 4;13(5):497-510. doi: 10.1039/d2md00006g. eCollection 2022 May 25.
3
Druggable Lipid Binding Sites in Pentameric Ligand-Gated Ion Channels and Transient Receptor Potential Channels.

本文引用的文献

1
The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin.用于蛋白质的OPLS(液体模拟优化势)势函数、环肽和克拉宾晶体的能量最小化。
J Am Chem Soc. 1988 Mar 1;110(6):1657-66. doi: 10.1021/ja00214a001.
2
Heteroadamantyl cannabinoids.异金刚烷类大麻素。
J Med Chem. 2010 Aug 12;53(15):5656-66. doi: 10.1021/jm100390h.
3
Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.
五聚体配体门控离子通道和瞬时受体电位通道中的可药物靶向脂质结合位点
Front Physiol. 2022 Jan 4;12:798102. doi: 10.3389/fphys.2021.798102. eCollection 2021.
4
Functionalized Cannabinoid Subtype 2 Receptor Ligands: Fluorescent, PET, Photochromic and Covalent Molecular Probes.功能化大麻素亚型 2 受体配体:荧光、正电子发射断层扫描、光致变色和共价分子探针。
ChemMedChem. 2020 Aug 5;15(15):1374-1389. doi: 10.1002/cmdc.202000298. Epub 2020 Jun 24.
5
Selective Photoaffinity Probe That Enables Assessment of Cannabinoid CB Receptor Expression and Ligand Engagement in Human Cells.选择性光亲和探针,可用于评估人细胞中大麻素 CB 受体的表达和配体结合情况。
J Am Chem Soc. 2018 May 16;140(19):6067-6075. doi: 10.1021/jacs.7b11281. Epub 2018 Feb 16.
6
Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor.PSNCBAM-1的新型类似物作为大麻素CB1受体的变构调节剂
Bioorg Med Chem. 2017 Dec 15;25(24):6427-6434. doi: 10.1016/j.bmc.2017.10.015. Epub 2017 Oct 16.
7
Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.绘制大麻素1受体变构位点:新型、强效且不可逆结合探针GAT100的关键分子决定因素和信号特征
ACS Chem Neurosci. 2016 Jun 15;7(6):776-98. doi: 10.1021/acschemneuro.6b00041. Epub 2016 Apr 25.
8
Synthesis and Properties of Fully-Conjugated Indacenedithiophenes.全共轭茚并二噻吩的合成与性质
Chem Sci. 2014 Mar 1;5(3):1008-1014. doi: 10.1039/C3SC53181C.
9
2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective.2012年药物化学奖获奖致辞。探寻大麻素之路:个人视角。
J Med Chem. 2014 May 22;57(10):3891-911. doi: 10.1021/jm500220s. Epub 2014 May 1.
10
Novel adamantyl cannabinoids as CB1 receptor probes.新型金刚烷类大麻素作为 CB1 受体探针。
J Med Chem. 2013 May 23;56(10):3904-21. doi: 10.1021/jm4000775. Epub 2013 May 14.
人CB2大麻素受体的配体结合结构:受体亚型特异性结合基序及GPCR激活建模的证据
Chem Biol. 2008 Nov 24;15(11):1207-19. doi: 10.1016/j.chembiol.2008.10.011.
4
Oxaza adamantyl cannabinoids. A new class of cannabinoid receptor probes.氧杂金刚烷基大麻素。一类新型大麻素受体探针。
J Org Chem. 2006 Sep 29;71(20):7800-4. doi: 10.1021/jo061352c.
5
Structural requirements for cannabinoid receptor probes.大麻素受体探针的结构要求。
Handb Exp Pharmacol. 2005(168):209-46. doi: 10.1007/3-540-26573-2_7.
6
Plant, synthetic, and endogenous cannabinoids in medicine.医学中的植物性、合成性和内源性大麻素。
Annu Rev Med. 2006;57:553-74. doi: 10.1146/annurev.med.57.011205.135648.
7
Cannabinoid pharmacology: the first 66 years.大麻素药理学:头66年
Br J Pharmacol. 2006 Jan;147 Suppl 1(Suppl 1):S163-71. doi: 10.1038/sj.bjp.0706406.
8
High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor.
J Med Chem. 2005 Oct 6;48(20):6423-9. doi: 10.1021/jm050272i.
9
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.内源性大麻素系统:药物靶点、先导化合物及潜在治疗应用。
J Med Chem. 2005 Aug 11;48(16):5059-87. doi: 10.1021/jm058183t.
10
Adamantyl cannabinoids: a novel class of cannabinergic ligands.金刚烷基大麻素:一类新型大麻素能配体。
J Med Chem. 2005 Jul 14;48(14):4576-85. doi: 10.1021/jm058175c.